# Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)

> **NCT05587088** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hospital Universitario San Ignacio** · enrollment: 82 (estimated)

## Conditions studied

- Neoplasm, Stomach
- Gastric Neoplasms Malignant
- Pancreatic Neoplasms
- Colorectal Neoplasms
- Acute Leukemia
- Acute Leukemia in Relapse
- Acute Leukemia Lymphoid
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia, in Relapse

## Interventions

- **DRUG:** Petiveria Alliacea Preparation
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05587088
- **Lead sponsor:** Hospital Universitario San Ignacio
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-15
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2022-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05587088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05587088, "Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05587088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*